泰格医药净利暴跌80%首度亏损 四重自救能否力挽狂澜?

新浪证券
10 Apr

3月27日,国内临床CRO龙头泰格医药交出上市12年来最惨淡成绩单:2024年营收66.03亿元,同比缩水10.58%;归母净利润仅4.05亿元,同比暴跌79.99%。更令市场哗然的是,第四季度单季亏损4.08亿元,创下公司历史首次季度亏损纪录。这一数据与其2021年超1800亿元的市值巅峰形成强烈反差,折射出中国创新药产业链从“黄金时代”到“冰河世纪”的剧烈震荡。周期之殇:“杠杆扩张”反噬效应...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10